가신길TV's video: ESMO 2020 EGFR : Amivantamab Lazertinib Phase 1 Anti-HER3 ADC U3-1402 Phase 1

@ESMO 2020 비소세포폐암 EGFR 시장의 새로운 흐름: ①Amivantamab+Lazertinib Phase 1 ②Anti-HER3 ADC U3-1402 Phase 1

여러분의 소중한 후원은 영상 제작에 큰 힘이 됩니다. 1. 투네이션 https://toon.at/donate/gasingiltv 2. 계좌: 우리은행 박병준, 1002-338-639696 3. 비즈니스 문의: gasingiltv@gmail.com 4. 페이스북: www.facebook.com/gasingiltv [영상 목차] 1. NSCLC EGFRm Amivantamab+Lazertinib Phase 1 1) Amivantamab MoA & Characteristic 2) Study Design 3) Safety 4) Efficacy: Osimertinib resistant, Chemo-naïve Patients 5) Efficacy: Treatment- naïve Patients 2. NSCLC EGFRm Amivantamab+Lazertinib Phase 3(vs Osimertinib) 3. NSCLC EGFR 1L 시장 간략 정리 4. Anti-HER3 ADC U3-1402 Phase 1 1) Study Design 2) U3-1402 anti-tumor activity & Diverse TKI resistance mechanisms 3) Efficacy 4) NSCLC EGFR 1L 관련 Anti-HER3 ADC U3-1402+Osimertinib Combination Therapy #조병철

#Amivantamab #Lazertinib #조병철

가신길TV

Subscribers
15.2K

Total Post
224

Total Views
41K

Avg. Views
3.4K

View Profile

This video was published on 2020-09-25 15:36:21 GMT by @%EA%B0%80%EC%8B%A0%EA%B8%B8TV on Youtube. 가신길TV has total 15.2K subscribers on Youtube and has a total of 224 video.This video has received 79 Likes which are lower than the average likes that 가신길TV gets . @%EA%B0%80%EC%8B%A0%EA%B8%B8TV receives an average views of 3.4K per video on Youtube.This video has received 18 comments which are lower than the average comments that 가신길TV gets . Overall the views for this video was lower than the average for the profile.가신길TV #Amivantamab #Lazertinib #조병철 has been used frequently in this Post.

가신길TV's video: ESMO 2020 EGFR : Amivantamab Lazertinib Phase 1 Anti-HER3 ADC U3-1402 Phase 1

Other post by @%EA%B0%80%EC%8B%A0%EA%B8%B8TV